Floatz logo

cc-5013

MRD

The First Affiliated Hospital of Soochow UniversityPhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the MRD cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
The First Affiliated Hospital of Soochow University
Phase 4BB
DARATUMUMAB
The First Affiliated Hospital of Soochow University
Phase 4BB
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 4BB
Carfilzomib
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
The First Affiliated Hospital of Soochow University
Phase 4BB

View all 15 →

Same molecule, other indications

cc-5013 is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →